Gabon Moves to Shield Sacred Iboga Plant From Western Drug Firms

Deep inside candlelit temples in Gabon, worshippers have gathered for generations to consume the bitter bark of a slow-growing rainforest shrub called Tabernanthe iboga. The plant holds sacred status in several Gabonese ritual traditions — and now sits at the center of a growing dispute over who controls its future.

Iboga's active compounds have attracted significant attention from researchers and pharmaceutical companies in the United States and elsewhere, who believe the plant could yield breakthrough treatments for addiction and certain mental health disorders. That commercial interest has put Gabon on alert, with officials and traditional communities concerned that outside actors could exploit the resource without compensating or crediting its origins.

Read more Barclays Cuts 5,000 Jobs Amid AI Productivity Push →

The dynamic echoes earlier controversies over ayahuasca, the Amazonian psychedelic brew that moved from indigenous ceremonial use into Western wellness and pharmaceutical circles, sparking similar debates about cultural appropriation and biopiracy. Iboga advocates fear the same trajectory — corporate patents filed abroad, profits flowing out, and a sacred tradition reduced to a raw material.

Gabon, where iboga grows natively in the central African rainforest, has signaled it intends to assert stronger protections over the plant, though the precise legal and diplomatic mechanisms remain a work in progress. Traditional custodians argue that decades — if not centuries — of accumulated knowledge about iboga's preparation and use deserve formal recognition under international frameworks governing biodiversity and indigenous heritage.

The outcome could set a precedent for how African nations negotiate with global pharmaceutical industries over plant-based medicines derived from their sovereign ecosystems. Continue reading at Business | The Guardian.